Navigation Links
Regeneron Announces March 2011 Investor Conference Presentations
Date:2/23/2011

TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011

  • RBC Capital Markets' 2011 Healthcare Conference at 10:00 a.m. Eastern Time on Wednesday, March 2, 2011

  • Cowen and Company 31st Annual Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, March 8, 2011

  • Barclays Capital 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, March 16, 2011

  • The sessions may be accessed through the Company’s web site, www.regeneron.com, on the Investor Relations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.

    Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.

    Peter DworkinInvestor Relations

    Corporate Communications914.345.7799

    914.345.7800michael.aberman@regeneron.com

    peter.dworkin@regeneron.com
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/22/2017)... 2017  Andre, DiMino, CEO of ADM Tronics Unlimited, ... innovative technologies and products, commented on ADMT,s third quarter ... 2017 in the Company,s quarterly report on Form 10Q ... Andre, DiMino stated "During the quarter ended December 31, ... a larger portion of our engineering efforts into the ...
    (Date:2/22/2017)... Summary Provides understanding and ... agreements entered into by the worlds leading healthcare ... Description The Global Myocardial Infarction Partnering ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
    (Date:2/22/2017)... Summary Provides understanding and ... and agreements entered into by the worlds leading ... http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global Congestive Heart ... access to partnering deals and agreements entered into ... - Trends in partnering deals - Top ...
    Breaking Medicine Technology:
    (Date:2/22/2017)... HEIGHTS, MICHIGAN (PRWEB) , ... February 22, 2017 ... ... and analysis of issues related to spine practices, is featuring Michigan neurosurgeon Jay ... is known as one of a small number of neurosurgeons in Michigan performing ...
    (Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
    (Date:2/22/2017)... ... February 22, 2017 , ... ... percent of those report that family members or friends have also commented about ... from hearing loss wear hearing aids. One reason, suggested by 89 percent of ...
    (Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
    (Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a ... into this insight and more in its latest episode of its Brains Over Brawn ... with social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. ...
    Breaking Medicine News(10 mins):